on AMOEBA (EPA:ALMIB)
Amoéba confirms its strategic pivot in the first half of 2024
Amoéba, a greentech company specializing in microbiological solutions, has announced results for the first half of 2024, marked by a strategic turning point. The company now aims to become an industrial and commercial company by 2025.
Two product lines were prioritized: biocontrol, awaiting approval by the US EPA and EFSA, and cosmetic products, which have shown promising results in clinical trials. Operating costs were reduced, improving operating income by more than €1 million.
Financially, the company benefits from the support of Nice & Green, ensuring financial visibility until June 30, 2025. The simple bond loan amounts to €8,074,000.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AMOEBA news